News | February 23, 2022
Sanofi India posts CY2021 PAT at Rs. 944.4 Cr
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Narayanan to lead SeQuent through next phase of consolidation and growth
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Flattish volume growth and subdued new launches were key factors for last month
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)